Cargando…

Neurobiologic Rationale for Treatment of Apathy in Alzheimer’s Disease With Methylphenidate

The public health burden of Alzheimer’s disease (AD) is related not only to cognitive symptoms, but also to neuropsychiatric symptoms, including apathy. Apathy is defined as a quantitative reduction of goal-directed activity in comparison to a previous level of functioning and affects 30%–70% of per...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Dyck, Christopher H., Arnsten, Amy F.T., Padala, Prasad R., Brawman-Mintzer, Olga, Lerner, Alan J., Porsteinsson, Anton P., Scherer, Roberta W., Levey, Allan I., Herrmann, Nathan, Jamil, Nimra, Mintzer, Jacobo E., Lanctôt, Krista L., Rosenberg, Paul B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7641967/ https://www.ncbi.nlm.nih.gov/pubmed/32461027 http://dx.doi.org/10.1016/j.jagp.2020.04.026

Ejemplares similares

The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): study protocol for a randomized controlled trial
por: Scherer, Roberta W., et al.
Publicado: (2018)

Effects of methylphenidate on neuropsychiatric symptoms in Alzheimer's disease: Evidence from the ADMET 2 study
por: Clark, Emily D., et al.
Publicado: (2023)

Effect of Methylphenidate for Apathy on Visual Attention Scanning Behavior: a Pilot Study
por: Chau, Sarah A., et al.
Publicado: (2018)

Diagnostic criteria for apathy in neurocognitive disorders
por: Miller, David S., et al.
Publicado: (2021)

The Neurobiology of Thought: The Groundbreaking Discoveries of Patricia Goldman-Rakic 1937–2003
por: Arnsten, Amy F.T.
Publicado: (2013)

Apathy: Neurobiology, Assessment and Treatment
por: Fahed, Mario, et al.
Publicado: (2021)

Use of methylphenidate in alzheimer’s dementia: Effect on apathy
por: Borralho, R., et al.
Publicado: (2021)

Global Council on Brain Health: Consensus and Recommendations for Promoting Brain Health Through Music Engagement
por: Mintzer, Jacobo
Publicado: (2020)

POTENTIAL BENEFITS OF THC AND CBD IN THE TREATMENT OF HOSPICE-ELIGIBLE DEMENTED AND AGITATED PATIENTS
por: Mintzer, Jacobo`
Publicado: (2022)

Apathy in Parkinson’s Disease: Clinical Patterns and Neurobiological Basis
por: Béreau, Matthieu, et al.
Publicado: (2023)

Methylphenidate improves prefrontal cortical cognitive function through α2 adrenoceptor and dopamine D1 receptor actions: Relevance to therapeutic effects in Attention Deficit Hyperactivity Disorder
por: Arnsten, Amy FT, et al.
Publicado: (2005)

Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition
por: Cummings, Jeffrey, et al.
Publicado: (2015)

Distinguishing apathy from depression: A review differentiating the behavioral, neuroanatomic, and treatment‐related aspects of apathy from depression in neurocognitive disorders
por: Lanctôt, Krista L., et al.
Publicado: (2023)

Combination pharmacotherapy in Alzheimer's disease
por: Mintzer, Jacobo, et al.
Publicado: (2003)

Behavioral and psychological signs and symptoms of dementia: a practicing psychiatrist's viewpoint
por: E. Mintzer, Jacobo, et al.
Publicado: (2000)

Selective serotonin reuptake inhibitors-associated apathy syndrome: A cross sectional study
por: Padala, Prasad R., et al.
Publicado: (2020)

A 12-Month Open-Label Extension Study of the Safety and Tolerability of Lisdexamfetamine Dimesylate for Major Depressive Disorder in Adults
por: Richards, Cynthia, et al.
Publicado: (2018)

The pocket idiot's guide to surviving an audit
por: Friedfel, Alan, et al.
Publicado: (2010)

Molecular Characterisation of the Mechanism of Action of Stimulant Drugs Lisdexamfetamine and Methylphenidate on ADHD Neurobiology: A Review
por: Quintero, Javier, et al.
Publicado: (2022)

Neuromodulation for Apathy in Alzheimer’s Disease: A Double-Blind, Randomized, Sham-Controlled Pilot Study
por: Padala, Prasad R., et al.
Publicado: (2020)

A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer’s disease patients with agitation
por: Akil, Ayman, et al.
Publicado: (2015)

The neurobiology of apathy in depression and neurocognitive impairment in older adults: a review of epidemiological, clinical, neuropsychological and biological research
por: Steffens, David C., et al.
Publicado: (2022)

International Review of Neurobiology, Vol. 16
por: van Dyck, Craig
Publicado: (1976)

Guanfacine’s mechanism of action in treating prefrontal cortical disorders: Successful translation across species
por: Arnsten, Amy F.T.
Publicado: (2020)

Distinct Subtypes of Apathy Revealed by the Apathy Motivation Index
por: Ang, Yuen-Siang, et al.
Publicado: (2017)

Apathy in Parkinson’s Disease: Defining the Park Apathy Subtype
por: De Waele, Ségolène, et al.
Publicado: (2022)

Brain amyloid burden, sleep, and 24-hour rest/activity rhythms: screening findings from the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration Studies
por: Spira, Adam P, et al.
Publicado: (2021)

Origins of Apathy
por: Mitchell, Alexander
Publicado: (1970)

Apathy or Activity?
por: Slater, Robert
Publicado: (1968)

Pain and apathy
por: Bahia, Valéria Santoro
Publicado: (2008)

Is there a Neurobiological Rationale for the Utility of the Iowa Gambling Task in Parkinson’s Disease?
por: Salvatore, Michael F., et al.
Publicado: (2021)

Drug-Induced Hematologic Syndromes
por: Mintzer, David M., et al.
Publicado: (2009)

Lifestyle Choices and Brain Health
por: Mintzer, Jacobo, et al.
Publicado: (2019)

A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease
por: Turner, R. Scott, et al.
Publicado: (2015)

Neonatal NIRS monitoring: recommendations for data capture and review of analytics
por: Vesoulis, Zachary A., et al.
Publicado: (2021)

Changes in QTc Interval in the Citalopram for Agitation in Alzheimer's Disease (CitAD) Randomized Trial
por: Drye, Lea T., et al.
Publicado: (2014)

Apathy in Alzheimer's disease
por: Nobis, Lisa, et al.
Publicado: (2018)

Guanfacine for the Treatment of Cognitive Disorders: A Century of Discoveries at Yale
por: Arnsten, Amy F.T., et al.
Publicado: (2012)

Are the Items of the Starkstein Apathy Scale Fit for the Purpose of Measuring Apathy Post-stroke?
por: Hum, Stanley, et al.
Publicado: (2021)

Assessment of apathy in neurological patients using the Apathy Motivation Index caregiver version
por: Klar, Verena S., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dsof3mtk9cm1kiqam8amu5r8ib